The Buzzing Trends || How ASX Is Performing Amid Buzzing Global Developments? скачать в хорошем качестве

The Buzzing Trends || How ASX Is Performing Amid Buzzing Global Developments?

Hi, You are watching Kalkine TV live from Sydney. This is The Buzzing Trends show. Lets get started with today’s important news that could impact markets. • The S&P/ASX200 is down just 2.30 points today to 7090.20. The bottom performing stocks in this index are COSTA GROUP HOLDINGS LIMITED down 24.10% and FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED, down 9.86%. Over the last five days, the index has gained 1.01% and is currently 1.15% off of its 52week high. •  Amazon.Com Inc. (NASDAQ:AMZN) said on May 26 that it agreed to buy Hollywood studio MGM for US$8.45 billion. • The acquisition of MGM would mark Amazon’s second-largest deal after it bought Whole Foods Market for US$13.7 billion in 2017.  • Moving on to COVID-19 related news. A new strain of SARS-CoV-2 B.1.617.2 that was first detected in India is becoming dominant and has been officially recorded in fifty-five territories, as per a World Health Organization (WHO) report. Vaccine developers are now testing their jabs for B.1.617.2 strain of coronavirus. Some UK studies reveal that the vaccines developed by Oxford-AstraZeneca and Pfizer-BioNTech were more than 80% effective against this new variant.  • Next news is from the EV space. Brisbane-based Tritium, a developer and manufacturer of direct current fast chargers for electric vehicles (EVs), has entered into a definitive agreement with a special purpose acquisition company (SPAC) Decarbonization Plus Acquisition Corporation II (NASDAQ:DCRN, DCRNW).  • Plenti Group Limited has delivered exceptional growth during the year ended 31 March 2021.  A growth of 33% was noted in renewable energy originations. • US President Joe Biden has upped the ante on investigation into the origins of the COVID-19 pandemic, ordering the US intelligence officials to conduct a detailed probe and report back in 90 days. • As per a World Health Organization (WHO) report. Vaccine developers are now testing their jabs for B.1.617.2 strain of coronavirus. • Moderna updated the market that its COVID-19 vaccine Phase 2/3 clinical trial in adolescents has met its primary immunogenicity endpoint. • The US-based pharmaceutical giant has developed mRNA based vaccine against COVID-19 with its partner BioNTech SE (NASDAQ:BNTX). • Sinopharm’s COVID-19 vaccine was awarded an emergency use approval from the World Health Organization (WHO). • Novavax is developing the recombinant protein-based COVID-19 vaccine named NVX-CoV2373 #asxstocks #modernavaccine #covid19vaccine #novavax sinopharmvaccine #originsofcovid19 #kalkinemedia To get more updates about Australia, NZ, UK & Canada stock market news, investors education & insights subscribe our channel at https://bit.ly/3cHKioy About us: Kalkine Media’s You Tube Channel is a one stop shop for all related news, updates, expert views, business insights etc. Catch ASX Daily market commentary, trending news stories for the day, market movers, stock information, top research stories, expert insights and much more only on Kalkine Media’s You Tube Channel. Check out our media Website 👉 https://kalkinemedia.com/au Follow us and stay updated on the Go with the Stock Market 👇👇 Facebook -   / kalkineau   Twitter -   / kalkineau   LinkedIN -   / 4829818